Results 181 to 190 of about 51,116 (225)
Some of the next articles are maybe not open access.
Spectrochimica Acta Part A - Molecular and Biomolecular Spectroscopy, 2023
A magnetic molecularly imprinted polymer (MIP) was synthesized by precipitation polymerization utilizing Fe3O4@SiO2-MPS as a magnetic core, itaconic acid as a functional monomer, azobisisobutyronitrile as an initiator, and ethylene glycol dimethacrylate ...
Nasibeh Azizi-Khereshki +5 more
semanticscholar +1 more source
A magnetic molecularly imprinted polymer (MIP) was synthesized by precipitation polymerization utilizing Fe3O4@SiO2-MPS as a magnetic core, itaconic acid as a functional monomer, azobisisobutyronitrile as an initiator, and ethylene glycol dimethacrylate ...
Nasibeh Azizi-Khereshki +5 more
semanticscholar +1 more source
American Journal of Cardiovascular Drugs, 2002
Valsartan, an orally active nonpeptide angiotensin II (AII) receptor antagonist with selectivity for the AII type I (AT(1)) receptor subtype, has recently been approved by the US Food and Drug Administration for the treatment of patients with heart failure (New York Health Association class II-IV) who are intolerant of ACE-inhibitor therapy.
Keri, Wellington, Karen L, Goa
+5 more sources
Valsartan, an orally active nonpeptide angiotensin II (AII) receptor antagonist with selectivity for the AII type I (AT(1)) receptor subtype, has recently been approved by the US Food and Drug Administration for the treatment of patients with heart failure (New York Health Association class II-IV) who are intolerant of ACE-inhibitor therapy.
Keri, Wellington, Karen L, Goa
+5 more sources
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial
Nature Medicine, 2021 Carolyn Y Ho +2 more
exaly +2 more sources
Circulation
BACKGROUND: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction.
Robert Shaddy +2 more
exaly +2 more sources
BACKGROUND: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction.
Robert Shaddy +2 more
exaly +2 more sources
Journal of Cardiology, 2023
BACKGROUND The characteristics, tolerability, and outcomes in patients with heart failure (HF) who are treated with sacubitril/valsartan remain unclear in Japan.
S. Matsumoto +11 more
semanticscholar +1 more source
BACKGROUND The characteristics, tolerability, and outcomes in patients with heart failure (HF) who are treated with sacubitril/valsartan remain unclear in Japan.
S. Matsumoto +11 more
semanticscholar +1 more source
Drugs, 1999
Valsartan/hydrochlorothiazide (HCTZ) combines an angiotensin II AT1 receptor blocker with a thiazide diuretic to produce additive blood pressure reductions without major effects on heart rate. HCTZ did not significantly alter valsartan pharmacokinetics; during combination therapy, HCTZ pharmacokinetics differed from those seen with HCTZ monotherapy. In
H D, Langtry, K J, McClellan
openaire +2 more sources
Valsartan/hydrochlorothiazide (HCTZ) combines an angiotensin II AT1 receptor blocker with a thiazide diuretic to produce additive blood pressure reductions without major effects on heart rate. HCTZ did not significantly alter valsartan pharmacokinetics; during combination therapy, HCTZ pharmacokinetics differed from those seen with HCTZ monotherapy. In
H D, Langtry, K J, McClellan
openaire +2 more sources
Circulation
BACKGROUND: A hypothetical concern has been raised that sacubitril/valsartan might cause cognitive impairment because neprilysin is one of several enzymes degrading amyloid-β peptides in the brain, some of which are neurotoxic and linked to Alzheimer ...
Pardeep S Jhund +2 more
exaly +2 more sources
BACKGROUND: A hypothetical concern has been raised that sacubitril/valsartan might cause cognitive impairment because neprilysin is one of several enzymes degrading amyloid-β peptides in the brain, some of which are neurotoxic and linked to Alzheimer ...
Pardeep S Jhund +2 more
exaly +2 more sources
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
New England Journal of Medicine, 2001 J. Cohn, G. Tognoni
exaly +2 more sources